SAN FRANCISCO, CA -- (MARKET WIRE) -- May 21, 2007 -- Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair® Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.
